Washington, DC 20006-5349
HELPLINE
MESOTHELIOMA NEWS
Scroll to find news of interest to you, or search by category. The Mesothelioma Applied Research Foundation covers mesothelioma news for patients and their families. Our write-ups are heavily reliant on peer-reviewed medical research studies with input from mesothelioma experts from around the world but are also accessible to non-medical readers.
Dr. James Stevenson, a thoracic oncologist at Cleveland Clinic, informs our community on how the COVID-19 pandemic is affecting his institution: Consultations: Available via telemedicine.
Dr. Antoinette Wozniak, a thoracic oncologist at the University of Pittsburgh Medical Center (UPMC), provides an update about her institution: Standard treatment: Available. Clinical trials: Paused
Dr. Charles Simone, the chief medical officer and a radiation oncologist focusing on mesothelioma at the New York Proton Center, discusses the contribution of proton
Dr. Patrick Forde, director of the Thoracic Cancer Clinical Research Program and associate professor of oncology at Johns Hopkins Medicine, gives an update on how
Mary Hesdorffer, NP, executive director of the Mesothelioma Applied Research Foundation, interviewed Boris Sepesi, MD, a thoracic surgeon at MD Anderson Cancer Center. The conversation
Members of the mesothelioma treatment team at the University of Maryland Medical Center — Joseph Friedberg, MD; Melissa Culligan, RN, MS; and Erica Glass, NP
Steve W. is a 56-year-old husband and father of three who was diagnosed with pleural mesothelioma in June 2018. Following his diagnosis, Steve and his
Bristol Myers Squibb announced today that CheckMate -743, a pivotal phase 3 trial evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in previously untreated malignant pleural mesothelioma, met its primary endpoint of overall